Thornburg Investment Management Inc Prothena Corp Public LTD CO Transaction History

Thornburg Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 08, 2024	SELL	$32.31 - $52.32 $86,590 - $140,217	-2,680 Reduced 9.48%	25,591 $929,000
Q3 2023 Nov 13, 2023	SELL	$47.3 - $70.6 $35,002 - $52,243	-740 Reduced 2.55%	28,271 $1.36 Million
Q2 2023 Aug 08, 2023	SELL	$48.26 - $78.59 $30,500 - $49,668	-632 Reduced 2.13%	29,011 $1.98 Million
Q1 2023 May 09, 2023	BUY	$46.97 - $58.27 $252,181 - $312,851	5,369 Added 22.12%	29,643 $1.44 Million
Q4 2022 Feb 07, 2023	BUY	$52.05 - $65.0 $1.26 Million - $1.58 Million	24,274 New	24,274 $1.46 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Thornburg Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Thornburg Investment Management Inc with notifications on news.